[Management View]
Edwards Lifesciences reported $1.53 billion in total sales for Q2 2025, up 10.6% YoY, driven by broad-based growth across the structural heart portfolio. Adjusted EPS was $0.67, with GAAP EPS at $0.57. Key strategic milestones included approvals for the CPNM3 platform in the asymptomatic TAVR indication and the CE Mark for Sapien M3.

[Outlook]
The company raised its full-year 2025 sales growth guidance to 9%-10% and adjusted EPS guidance to the high end of $2.40 to $2.50. Management expects annual constant currency operating profit margin expansion starting in 2026, with a target of a 50-100 basis point increase per year.

[Financial Performance]
- Total Sales: $1.53 billion, up 10.6% YoY
- Adjusted EPS: $0.67
- GAAP EPS: $0.57
- TAVR Global Sales: $1.1 billion, up 7.8% YoY
- TMTT Sales: $133 million, up 57% YoY
- Surgical Sales: $267 million, up 6.8% YoY
- Adjusted Gross Profit Margin: 77.6%
- SG&A Expenses: $502 million
- R&D Expense: $276 million
- Adjusted Operating Margin: 28.2%
- Cash Position: $3 billion

[Q&A Highlights]
Question 1: US TAVR performance exceeded expectations. What drove this, and is asymptomatic already contributing?
Answer: The quarter was better than expected for TAVR, driven by renewed focus on patient management and early TAVR study conversations. Asymptomatic patients are not yet a significant factor, but the clinical community's attention on severe aortic stenosis management has increased.

Question 2: Can you discuss outside US trends, particularly in Japan and Europe?
Answer: In Europe, the rollout of the S3 UR platform is progressing well, and the recent asymptomatic indication is expected to be a game-changer. In Japan, efforts are focused on expanding therapy and regaining market share lost to new competitors.

Question 3: Why not raise EPS guidance further given the strong quarter and reduced tariff impact?
Answer: Despite a strong quarter, headwinds like the GenaValve acquisition impact remain. The company raised EPS guidance to the high end of $2.40 to $2.50, maintaining a cautious approach.

Question 4: What is the impact of the international competitor's exit on market share?
Answer: The focus was on ensuring inventory and training at centers using the competitor's technology. Long-term, the company aims to highlight the value of its technology and maintain its price point.

Question 5: When do you expect CMS to reopen the NCD, and what are the implications of moving to a single operator?
Answer: The timing is uncertain, but the company is working with CMS to update the NCD. Streamlining operator and facility requirements would improve patient access and care, potentially allowing both surgeon-led and cardiology-led TAVR teams.

Question 6: What are the real-world outcomes for Evoque, and how is the learning curve affecting results?
Answer: Real-world outcomes for Evoque are similar or better than the TRISCEND II trial. Continuous data generation and innovation are expected to improve outcomes further.

Question 7: What is the potential impact of the NCD update on capacity and volumes?
Answer: The update could significantly increase capacity by reducing operator and facility requirements, allowing more centers to perform TAVR procedures.

Question 8: How is the TMTT portfolio performing, and what are the growth drivers?
Answer: The TMTT portfolio, including PASCAL and EVOQUE, is driving impressive growth. The recent CE Mark approval for Sapien M3 and ongoing clinical data generation are expected to support further expansion.

[Sentiment Analysis]
Analysts and management maintained a positive tone, highlighting strong performance, strategic milestones, and future growth potential. Management expressed confidence in achieving long-term targets despite some headwinds.

[Quarterly Comparison]
| Metric | Q2 2025 | Q2 2024 | YoY Change |
|----------------------------|---------------|---------------|-------------|
| Total Sales | $1.53 billion | $1.38 billion | +10.6% |
| Adjusted EPS | $0.67 | $0.61 | +9.8% |
| GAAP EPS | $0.57 | $0.55 | +3.6% |
| TAVR Global Sales | $1.1 billion | $1.02 billion | +7.8% |
| TMTT Sales | $133 million | $85 million | +57% |
| Surgical Sales | $267 million | $250 million | +6.8% |
| Adjusted Gross Profit Margin| 77.6% | 80% | -2.4% |
| SG&A Expenses | $502 million | $448 million | +12.1% |
| R&D Expense | $276 million | $272 million | +1.5% |
| Adjusted Operating Margin | 28.2% | 27.5% | +0.7% |

[Risks and Concerns]
- Potential impact of tariffs and foreign exchange fluctuations
- Integration and financial impact of the GenaValve acquisition
- Regulatory and reimbursement challenges for new product approvals

[Final Takeaway]
Edwards Lifesciences delivered a strong Q2 2025 performance, driven by robust growth across its structural heart portfolio. The company raised its full-year sales and EPS guidance, reflecting confidence in its strategic initiatives and market position. Key milestones, including product approvals and clinical data, support long-term growth prospects. While some headwinds remain, management's focus on innovation and execution positions the company well for future success.